ES2453391B2 - Recombinant Haemonchus contortus protein and its application for the production of a vaccine against hemoncosis. - Google Patents
Recombinant Haemonchus contortus protein and its application for the production of a vaccine against hemoncosis. Download PDFInfo
- Publication number
- ES2453391B2 ES2453391B2 ES201200865A ES201200865A ES2453391B2 ES 2453391 B2 ES2453391 B2 ES 2453391B2 ES 201200865 A ES201200865 A ES 201200865A ES 201200865 A ES201200865 A ES 201200865A ES 2453391 B2 ES2453391 B2 ES 2453391B2
- Authority
- ES
- Spain
- Prior art keywords
- protein
- hemoncosis
- production
- recombinant
- contortus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000243974 Haemonchus contortus Species 0.000 title abstract 4
- 102000004169 proteins and genes Human genes 0.000 title abstract 4
- 108090000623 proteins and genes Proteins 0.000 title abstract 4
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 2
- 230000004224 protection Effects 0.000 abstract 2
- 241000186427 Cutibacterium acnes Species 0.000 abstract 1
- 241000588724 Escherichia coli Species 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 241001494479 Pecora Species 0.000 abstract 1
- 108020004511 Recombinant DNA Proteins 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000002158 endotoxin Substances 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 230000002480 immunoprotective effect Effects 0.000 abstract 1
- 229920006008 lipopolysaccharide Polymers 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000001823 molecular biology technique Methods 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 229940055019 propionibacterium acne Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
- C07K14/4354—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0003—Invertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
Abstract
Proteína recombinante de Haemonchus contortus y su aplicación para la producción de una vacuna frente a la hemoncosis.#Se ha procedido a la obtención de una proteína recombinante (rHc23) de H. contortus tras comprobar que la proteína nativa Hc23, de 23kDa de peso molecular, originaria del extracto soluble de adultos del nematodo hematófago H. contortus ha mostrado capacidad inmunoprotectora en el ganado ovino joven de 5 meses de edad frente a la trichostrongilidosis más importante (hemoncosis) desde un punto de vista económico y patológico.#Se ha caracterizado la proteína Hc23, obteniéndose las secuencias aminoacídicas y genómicas de la misma, permitiendo, por técnicas de biología molecular, ADN recombinante, la producción de una proteína estable, la rHc23. Su utilización en composiciones inmunogénicas que incluyen como adyuvante la combinación de Propionibacterium acnes inactivado + lipopolisacáridos de E. coli ha mostrado un elevado grado de protección en los animales (>85% de protección).Recombinant protein of Haemonchus contortus and its application for the production of a vaccine against hemoncosis. # A recombinant protein (rHc23) of H. contortus has been obtained after verifying that the native protein Hc23, 23kDa molecular weight Originally from the soluble extract of adults of the hematophagous nematode H. contortus has shown immunoprotective capacity in young sheep of 5 months of age against the most important trichostrongilidosis (hemoncosis) from an economic and pathological point of view. Hc23 protein, obtaining the amino acid and genomic sequences thereof, allowing, by molecular biology techniques, recombinant DNA, the production of a stable protein, rHc23. Its use in immunogenic compositions that include as an adjuvant the combination of inactivated Propionibacterium acnes + E. coli lipopolysaccharides has shown a high degree of protection in animals (> 85% protection).
Description
Claims (1)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201200865A ES2453391B2 (en) | 2012-09-05 | 2012-09-05 | Recombinant Haemonchus contortus protein and its application for the production of a vaccine against hemoncosis. |
| PCT/ES2013/000197 WO2014037592A1 (en) | 2012-09-05 | 2013-09-04 | Recombinant protein ofhaemonchus contortus and use thereof for the production of a vaccine against haemonchosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201200865A ES2453391B2 (en) | 2012-09-05 | 2012-09-05 | Recombinant Haemonchus contortus protein and its application for the production of a vaccine against hemoncosis. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2453391A1 ES2453391A1 (en) | 2014-04-07 |
| ES2453391B2 true ES2453391B2 (en) | 2014-08-14 |
Family
ID=50236572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES201200865A Active ES2453391B2 (en) | 2012-09-05 | 2012-09-05 | Recombinant Haemonchus contortus protein and its application for the production of a vaccine against hemoncosis. |
Country Status (2)
| Country | Link |
|---|---|
| ES (1) | ES2453391B2 (en) |
| WO (1) | WO2014037592A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110221060B (en) * | 2019-06-23 | 2021-04-13 | 南京农业大学 | Antigen for early diagnosis of haemonchus contortus infection and application thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5747046A (en) * | 1989-03-17 | 1998-05-05 | Munn; Edward Albert | Vaccine containing a protein complex form Haemonchus contortus |
| DE69205243T2 (en) * | 1991-02-06 | 1996-06-13 | Biotech Australia Pty. Ltd., Roseville, New South Wales | VACCINE AGAINST NEMATODES. |
| GB0617962D0 (en) * | 2006-09-13 | 2006-10-18 | Moredun Res Inst | Novel nematode protein and its use in producing anthelminthic agents and vaccines |
| GB0815674D0 (en) * | 2008-08-28 | 2008-10-08 | Moredun Res Inst | Nematode vaccine |
-
2012
- 2012-09-05 ES ES201200865A patent/ES2453391B2/en active Active
-
2013
- 2013-09-04 WO PCT/ES2013/000197 patent/WO2014037592A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| ES2453391A1 (en) | 2014-04-07 |
| WO2014037592A1 (en) | 2014-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124592T1 (en) | 3-PHENYLISOXAZOLINE-5-CARBOXAMIDES HERBICIDIC ACTIVE FORMULATED FROM TETRAHYDRO- AND DIHYDROFURANCARBOXYLIC ACIDS AND ESTERS | |
| AR121016A2 (en) | PHENOTHIAZINDIAMINUM SALTS AND THEIR USE | |
| CY1120622T1 (en) | METHODS AND COMPOSITIONS FOR INDICATION OF AN IMMUNE RESPONSE TO EGFRVIII | |
| CY1122793T1 (en) | CHLORIDE SALT OF TAT-NR2B9C | |
| CY1120319T1 (en) | Fusion proteins and fusion vaccines comprising HAEMOPHILUS INFLUENZAE PROTEIN E AND PILIN A | |
| CO2017012893A2 (en) | Pharmaceutical compositions comprising neo-antigen peptides or a salt thereof and methods for preparing the same | |
| BR112016015422A2 (en) | single vial vaccine formulations | |
| DK4097078T3 (en) | Amino acid surfactants | |
| PY1548374A (en) | Recombinant FMDV vaccines and their uses | |
| CY1126231T1 (en) | HUMAN ALPHA-GALCATOSIDASE VARIANTS | |
| MX377804B (en) | COMPOSITIONS USEFUL IN THE TREATMENT OF ORNITHINE TRANSCARBAMYLASE (OTC) DEFICIENCY. | |
| EA201400912A1 (en) | RECOMBINANT POXVIRUS VECTORS, EXPRESSING PROTEINS OF THE RABOR AND OX40 VIRUS, AND VACCINES ESTABLISHED ON THEIR BASIS | |
| MX2017008817A (en) | COMPOSITIONS AND METHODS FOR THE GLYCOSILATION OF PROTEINS. | |
| CY1120430T1 (en) | RECOMMENDED CDV COMPOSITIONS AND USES OF THESE | |
| DK3355856T3 (en) | ORALLY ADMINISTERED AMINO ACID FORMULATIONS WITH MODIFIED RELEASE | |
| UY35455A (en) | TRIPEPTIDIC INHIBITORS OF PROTEASA EPOXYCETONE | |
| ECSP17044282A (en) | Insulin glargine / lixisenatide fixed ratio formulation | |
| EP3528839C0 (en) | EXPEC GLYCOCONJUGATE VACCINE FORMULATIONS | |
| MX2015011487A (en) | PROTEIN OF CONSENSUS FOR THE VIRUS OF THE DISEASE OF THE AFTOSA FEVER (FMDV), CODIFICATION SEQUENCES FOR THESE AND VACCINES ELABORATED FROM THESE. | |
| EA201991023A1 (en) | PHARMACEUTICAL COMPOSITION FOR Parenteral Administration Containing Karglum Acid | |
| EA201690115A1 (en) | COMBINED IMMUNOGENIC COMPOSITIONS | |
| EP3307338A4 (en) | NOVEL HYALURONIC ACID HYDROGELS HAVING MEDICAL APPLICATIONS | |
| AR099960A1 (en) | PROCEDURES AND PHARMACEUTICAL COMPOSITION TO INDUCE AN IMMUNE RESPONSE | |
| MX2016013559A (en) | Stable protein formulations comprising a molar excess of sorbitol. | |
| CL2017002326A1 (en) | Treatment of patients with type 2 diabetes mellitus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 2453391 Country of ref document: ES Kind code of ref document: B2 Effective date: 20140814 |